Search

Your search keyword '"Legnaghi, Elena"' showing total 3 results
Start Over Author "Legnaghi, Elena" Publication Type Academic Journals
3 results on '"Legnaghi, Elena"'

1. Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structure-Activity Relationship.

Author

Vianello, Paola, Sartori, Luca, Amigoni, Federica, Cappa, Anna, Fagá, Giovanni, Fattori, Raimondo, Legnaghi, Elena, Ciossani, Giuseppe, Mattevi, Andrea, Meroni, Giuseppe, Moretti, Loris, Cecatiello, Valentina, Pasqualato, Sebastiano, Romussi, Alessia, Thaler, Florian, Trifiró, Paolo, Villa, Manuela, Botrugno, Oronza A., Dessanti, Paola, and Minucci, Saverio

Published
2017
Full Text
View/download PDF

2. Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration.

Author

Sartori, Luca, Mercurio, Ciro, Amigoni, Federica, Cappa, Anna, Fagá, Giovanni, Fattori, Raimondo, Legnaghi, Elena, Ciossani, Giuseppe, Mattevi, Andrea, Meroni, Giuseppe, Moretti, Loris, Cecatiello, Valentina, Pasqualato, Sebastiano, Romussi, Alessia, Thaler, Florian, Trifiró, Paolo, Villa, Manuela, Vultaggio, Stefania, Botrugno, Oronza A., and Dessanti, Paola

Published
2017
Full Text
View/download PDF

3. Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.

Author

Amigoni F, Legnaghi E, and Pevarello P

Subjects
Animals, Central Nervous System Agents pharmacology, Central Nervous System Diseases enzymology, Central Nervous System Diseases physiopathology, Drug Design, Humans, Molecular Targeted Therapy, Neurodegenerative Diseases drug therapy, Neurodegenerative Diseases enzymology, Neurodegenerative Diseases physiopathology, Patents as Topic, Protein Kinase Inhibitors pharmacology, Central Nervous System Agents therapeutic use, Central Nervous System Diseases drug therapy, Protein Kinase Inhibitors therapeutic use
Abstract

Protein kinases (PKs), as members of an important target class in current pharmaceutical research, have been mostly exploited so far in therapeutic areas such as oncology and inflammation. However, basic research on some PKs as key components of molecular mechanisms underlying neurodegeneration and neuroprotection may translate into new medicines for CNS diseases in the next few years. This review is an account of recent patents dealing with kinase inhibitors primarily designed for CNS indications. CNS-directed patents on kinase modulators published after 2008 were surveyed using SciFinder(®) and public patent search engines. Some PK targets, such as GSK-3β, CDK5, ROCK and p38α MAPK, continue to attract interest even though a clinical proof-of-concept is yet to be attained in a CNS setting. Less established PKs such as LRRK2, MLK, PAK and DAPK-1 hold promise as valuable targets of the future.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results